MedTrace Logo

Efficacy and Safety of LEO 19123 Cream in the Treatment of Psoriasis Vulgaris

NCT00764751 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2025-03-07

Study results available
· View outcomes & findings →

Summary

This study will compare the efficacy and safety of once daily treatment of LEO 19123 cream versus Dovonex® cream (applied twice daily) and versus LEO 19123 cream vehicle alone (applied twice daily) in subjects with psoriasis vulgaris. Subject will be treated for 4 weeks. All subjects will apply LEO 19123 cream to psoriasis lesions on the left or right side of the body and either Dovonex® cream or cream vehicle to lesions on the other side.

Conditions

  • Psoriasis Vulgaris

Interventions

DRUG

LEO 19123 Cream (calcipotriol plus LEO 80122)

Once daily application

DRUG

Dovonex® cream

Twice daily application

DRUG

Cream vehicle

Twice daily application

Sponsors & Collaborators

  • LEO Pharma

    lead INDUSTRY

Principal Investigators

  • Rodion Kunynetz, MD · UltraNova Skincare

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2008-12-31
Completion
2009-01-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00764751 on ClinicalTrials.gov